Parexel, a prominent clinical research organization (CRO), has unveiled its CEO succession plan, marking a significant transition in its leadership. Peyton Howell, currently serving as Chief Operating and Growth Officer, is set to assume the role of Chief Executive Officer effective May 15, 2024, succeeding Jamie Macdonald. Mr. Macdonald will retire as CEO but will continue to serve on the Board of Directors until December 31, 2024.

Under Mr. Macdonald’s stewardship, Parexel experienced substantial growth and achieved remarkable milestones, including its successful acquisition by EQT and Goldman Sachs Asset Management in 2021. Sheri McCoy, Chairperson of the Board, expressed gratitude for Mr. Macdonald’s leadership, acknowledging his pivotal role in positioning Parexel for sustainable growth.

Peyton Howell, hailed as a strategic leader, brings a wealth of experience to her new role. Having joined Parexel in 2018, Ms. Howell demonstrated her capabilities as Chief Commercial and Strategy Officer before assuming her current position. Her tenure witnessed the implementation of patient-focused strategies and the successful establishment of Parexel’s Biotech business unit.

Expressing her honor at the opportunity to lead Parexel, Ms. Howell reiterated the company’s commitment to patient-centricity and innovation. She emphasized collaboration with Jamie Macdonald during the transition and outlined her vision for Parexel’s future, focusing on strategic initiatives, profitable growth, and stakeholder value.

Ms. Howell’s extensive industry experience, including leadership roles at AmerisourceBergen and Lash Group, positions her well to guide Parexel through its next phase of development. She currently serves as Chairperson of the Association of Clinical Research Organizations (ACRO) and sits on the Board of Directors of Tandem Diabetes Care.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.